Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.72
- Piotroski Score 2.00
- Grade Buy
- Symbol (VIGL)
- Company Vigil Neuroscience, Inc.
- Price $2.98
- Changes Percentage (-2.29%)
- Change -$0.07
- Day Low $2.96
- Day High $3.07
- Year High $6.06
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $11.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.12
- Trailing P/E Ratio -2.17
- Forward P/E Ratio -2.17
- P/E Growth -2.17
- Net Income $-82,638,000
Income Statement
Quarterly
Annual
Latest News of VIGL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
Investing in unprofitable companies like Amazon can be lucrative, but the risk of cash burn is real. Analyzing Vigil Neuroscience's cash burn and runway, it's crucial to assess its growth potential an...
By Yahoo! Finance | 1 month ago -
The Ultimate Guide To MSC Meraviglia, By MSC Cruises
The MSC Meraviglia, named by Sophia Loren, is a luxurious cruise ship with Italian chic design. Offering a taste of the Mediterranean lifestyle, it features glitzy bars, circus shows, gourmet dining, ...
By Forbes | 2 months ago -
Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stocks to Buy Now?
A list of top biotech penny stocks includes Vigil Neuroscience, Inc. (NASDAQ:VIGL), focusing on neurodegenerative diseases. With promising clinical trials, analysts predict a potential 309.15% price i...
By Yahoo! Finance | 4 months ago
